BioPharma Resources

Drug Trial Radar · NCT07088263

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

A Prospective, Multicenter Phase Ⅲ Clinical Trial of Adaptive Chemotherapy for Advanced Breast Cancer After Standard Treatment

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Jul 24, 2027

Study completion Jun 24, 2028

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.

Conditions

  • Breast Neoplasms

Interventions

  • Gemcitabine, Vinorelbine, Eribulin, or UtideloneDrug

    Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival (PFS)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.